Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and small molecule therapies for ophthalmic disorders, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.
CEO George Magrath, MD, and Chief Scientific and Development Officer Ash Jayagopal, Ph.D., MBA, will deliver a corporate update presentation, available on demand starting September 8, 2025 at 7:00 a.m. ET. The company also noted that replays from recent investor events, including a Nasdaq Spotlight interview and other presentations, are available on their website's Investors section.
Positive
- None.
Negative
- None.
News Market Reaction – IRD
In the Sep 3 session, IRD gained 4.07%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jayagopal, Ph.D., MBA, Chief Scientific and Development Officer, will deliver a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. The presentation will be available on demand on Monday, September 8, 2025 at 7:00 a.m. ET.
In addition, replays from other recent investor events are available on the Opus Genetics’ website, including:
- Nasdaq Spotlight interview
- Chardan Virtual Ophthalmology Summit Series on Rare Ophthalmic Diseases Fireside Chat
- Jones Trading Virtual Presbyopia Expert Panel
Links to these webcasts may be accessed on the Opus Genetics website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
